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Summary In a population-based study of 115 children with non-B-cell acute lymphoblastic leukaemia, we
analysed the relation of the degree of leukopenia and risk of relapse to the degree of hepatotoxicity (as
measured by serum aminotransferase (AT)) during oral methotrexate (MTX) and 6-mercaptopurine (6MP)
maintenance chemotherapy (MT). Hepatotoxicity was calculated as a mean of all AT-measurements (mATMT).
Lack of hepatotoxicity was defined as a mATMT < 40 IU I -. A highly significant correlation was demon-
strated between the mean AT during the first, second, and third year of MT (r > 0.70, P < 0.00001). mATMT
was not related to the mean WBC during MT (r = - 0.03, P = 0.36), but was related to the rise in WBC
following cessation of therapy (r = 0.24, P = 0.06). Patients with recurrent disease had significantly lower
mATMT than patients staying in remission (P = 0.03 for both over-all and haematological relapse risk).
Patients with a mATMT >40 IU 1' had a lower risk of relapse than patients with a mATMTA40 IU 1-' (4.5
year CCR: 0.70 and 0.50, P = 0.06; and 4.5 year haematological remission: 0.83 and 0.63, P = 0.03). The
favourable outcome for patients with hepatotoxicity could be demonstrated for all risk groups.
Methotrexate (MTX) and 6-mercaptopurine (6MP) are
potential inducers of liver damage, and pathological liver
function tests and biopsies are frequently encountered with
oral MTX and 6MP maintenance therapy (MT) for child-
hood acute lymphoblastic leukaemia (ALL) (Nesbit et al.,
1976; McIntosh et al., 1977; Topley et al., 1979; Parker et al.,
1980; Menard et al., 1980; Harb et al., 1983). As the chance
for long-term disease-free survival improves, chronic side
effects of therapy like liver dysfunction gains increasing
importance. However, recurrent disease still remains the
major risk for these children, and dose reductions or with-
drawal of therapy in case of abnormal liver function tests
could well be more harmful that continued treatment. Recog-
nising the large inter-individual variations in the phar-
macokinetics of oral MTX and 6MP (Poplack et al., 1986;
Lennard et al., 1983; Schmiegelow et al., 1990), the degree of
hepatotoxicity may reflect the magnitude of systemic drug
exposure, i.e. the impact of therapy, as have been indicated
by some studies (Parker et al., 1980; Schmiegelow et al.,
1990), and hepatoxicity could thus be a possible favourable
feature in respect to prognosis.
In the present population-based study of non-B-cell ALL
in children > 1 year of age, we have analysed hepatotoxicity
(measured by the rise in aspartate or alanine aminotrans-
ferases (AT)) during MT, and its relation to drug dosage and
to myelodepression (measured by the mean white cell count),
as well as its relation to relapse risk.
Patients and methods
Patients
From July 1981 to December 1985, >90% of all new
Danish cases of non-B-cell ALL > 1 and < 15 years of age
were treated by common therapy programmes (Figure 1).
One hundred and twenty-eight patients completed induction
and consolidation therapy. Of these, 13 were excluded from
this study due to major protocol violation during induction
or consolidation therapy, refusal of MT by parents, AT not
measured during MT, or lack of data (3, 1, 7 and 2 patients).
Thus, 115 patients (67 boys and 48 girls) were eligible for
analyses, with 56 cases of standard risk (SR), 39 cases of
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Figure 1 Treatment regimens. A = adriamycin (IR-patients
40 mg m-2; HR-patients 25 mgm-2); M = asparginase
1,000 IU kg-' day-' i.v.; E111 = asparginase 5,000 IU kg-'
day-' i.v.; ASP = 10,000 IU kg-'day-' i.v.; CYC = cyclophos-
phamide (I g m 2 i.v.); M = cytosar-arabinoside (75 mg m-2 i.v.
daily for 4 days); 6MP = oral 6-mercaptopurine (75 mg m-2
day-'); MTX = oral methotrexate (20 mg m-2 week-'); M = int-
rathecal methotrexate (12 mg m 2); pred/p = oral prednisone
(60 mg m-2 day-'); - = 6-thioguanine (60 mg m 2 day-'); |
/ M = 500/1,000 mg MTX 24 h infusion with leucovorin rescue;
V = vincristine (2mg m2, max. 2mgdose-'); XXXX = CNS-
irradiation (2,400 cGy).
intermediate risk (IR) and 20 cases of high risk ALL. Criteria
for risk classification are given in Table I.
Duration of remission is the number of days between
compete clinical remission and end of follow-up (1 November
1988), or first positive manifestation of relapse (>5% blast
in bone-marrow, or any extramedullary, histologically con-
firmed leukaemia). For patients still in remission, median
length of follow-up from achieved remission was 60 months
(range: 34-87 months). No patients in continuous complete
remission (CCR) died or were lost for follow-up. One patient
with HR-ALL had a bone-marrow transplantation in first
remission during the first year of MT and was censored at
this event (Simon & Wittes, 1985).
Therapy
Therapy depended on risk classification (Figure 1). MT with
weekly oral MTX (target dose: 20 mgm2 ) and daily oral
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Table I Criteria for risk-classification
Standard risk 1. WBC <20 x 109 1-'
2. Age >2 and <10 years
3. No CNS-leukaemia or mediastinal mass
4. Non-T-cell ALL
Intermediate risk 1. WBC > 20 and <50 x 09 1-
2. Age<2 or ) 10 years, and WBC<50 x
109 1l'
3. No CNS-leukaemia or mediastinal mass
4. Non-T-cell ALL
High risk One or more of the following:
1. WBC5> x1091-'
2. CNS-leukaemia
3. Mediastinal mass
4. T-cell ALL
Patients with B-cell ALL and patients < 1 year at diagnosis are not
included.
6MP (target dose: 75 mg mr2) was started 10-12 weeks from
remission with dose adjustments determined by blood counts
(target WBC: 1.5-4.0 x 1091-') and presence of toxicity.
Drug dosage was reduced for WBC <1.5 x 1091-', both
drugs being withdrawn at WBC < 1.0 x 109 1-'. All patients
with IR-ALL received 3-5 cycles of alternating therapy of
reinductions or 24 h intravenous high dose MTX-infusions
(HDM) at 4-week intervals during the first 6-9 months of
MT. In addition, patients with IR-ALL diagnosed before
1983 (11 patients) and all patients with HR-ALL received
reinductions every third month throughout MT. Therapy was
for all patients discontinued after three years of CCR.
During MT and for at least 12 months after cessation of
therapy, haemoglobin, white cell (WBC) and platelet counts
were done at least monthly. Routine absolute neutrophile
counts (ANC) were not part of the protocols. ANC were
determined together with WBC for 59 patients. AT was
measured regularly during MT, but the intervals between
sampling differed. AT was for 17 patients measured together
with blood counts; i.e. at least monthly. For 63 patients, AT
was measured every 6-8 weeks, and for the remaining 25
patients at longer intervals (median interval: 4 months). AT
was determined as described elsewhere (Scandinavian Com-
mittee on Clinical Chemistry, 1974). Bone-marrow and spinal
fluid tests were done before the cessation of therapy, every
third month for the first year off treatment, and beyond this
only at suspicion of relapse. Cases of haematological relapse
include relapses in combination with extramedullary disease.
CNS (central nervous system) and testicular relapses are all
isolated relapses, and are counted as censoring observations
in respect to haematological remission (Simon & Wittes,
1985).
Drug dosage
For each patient, the average dose of MTX and 6MP per m2
were calculated as the cumulated prescribed dose per m2
divided by the period from start of MT until relapse, cessa-
tion of therapy or end of follow-up, whichever came first.
The duration of withdrawal of MTX and 6MP during MT
due to toxicity or febrile illness were calculated as a percen-
tage of the length of MT.
WBC
For every patient, a mean WBC was calculated for the
period of MT until relapse, end of therapy or end of follow-
up (mWBCMT). For patients completing MT, a mean WBC
was calculated for the third year of MT (mWBC3y). They
were calculated as weighted means of all WBC measure-
ments: mWBCMT =(M4WBC. x (D.,+I -Df))/LMT, mWBC3y
F (I4FWBC, x (D,+ -Dn))/365, where WBCn is the white
cell count at date n, DF and DL are the first and the last days
of the period included in the analyses, and LMT iS the length
of MT. Thus, each WBC was weighted according to the
intervals between sampling. For patients being at least 10
months off therapy in first remission, a mean WBC after
cessation of therapy (mWBC0ff) was similarly calculated for a
period delimited by the date after which the intervals between
WBC measurements exceeded 10 weeks (median length: 19
months, 10-33). Calculations of mWBC0ff included every
white cell count measured from one month off therapy and
throughout the period. The rise in mWBC following cessa-
tion of therapy was calculated as mWBC0ff-mWBC3y.
Similarly a mANCMT and the rise in mANC were calculated
for the 59 patients with regular ANC determinations.
Hepatotoxicity
For each patient, the degree of hepatotoxicity was calculated
as a weighted mean of all AT determinations available dur-
ing each year of MT (mAT,y, mAT2y, mAT3y) excluding those
within 3 weeks after HDM. mAT were calculated as: mAT =
(FPn x AT,)/I FPn, where Pn = (Dn+ -DO), Dn I I is the first
date to follow with blood counts, whether or not it includes
measuring of AT, DF is the first and DL the last date with
AT measurements of the year in question ATn is the AT
value on date Dn. Similarly, a mean AT was calculated for
the whole period of MT (mATMT). Patients were defined as
not having hepatotoxicity, if mATMT was <40IU1-'.
Due to persistent, severe hepatotoxicity, oral MTX was in
13 patients substituted with oral cyclophosphamide (100mg
m-2day-'). These patients were all censored at the time of
cyclophosphamide/MTX subsititution (Simon & Wittes,
1985).
Statistical analyses
Cox proportional hazards regression analysis with maximum
partial likelihood ratio tests was applied to a set of variables
to detect possible prognostic factors as well as the combined
and independent significance of these (Cox, 1972). In the
stepwise multivariate analysis, additional parameters were
included in the combined model only if their level of signi-
ficance was <0.10. The Kaplan-Meier method was applied
to estimate remission duration and to generate relapse-free
survival curves (Kaplan & Meier, 1958). Remission duration
of subgroups were compared with the generalised Savage test
(Mantel, 1966).
Results
The median mATMT was 48 IU 1I (range: 17-287) (Figure
2). Forty patients had a mATMT .40 IU -'. Nine of these
40 patients never had an AT of >40IUI-' during MT,
whereas intermittent rises in AT of >40 IU 1- were found
in the remaining 31 patients.
For the total material there was no significant differences
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Figure 2 Histogram of mean alanine aminotransferases
(mATMT) (IU 1-') during maintenance therapy (115 patients).
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in the prevalence of hepatotoxicity during the first, second,
and third year of MT (median values for mAT1y= 53,
mAT2y= 50, mAT3y=49 IUI-'). Neither risk group (which
includes previous therapy), gender, or age significantly influ-
enced mATMT, and there was no significant relation between
mATMT and the interval between samplings, although there
was a trend towards patients with hepatotoxicity having AT
measured at shorter intervals than patients with normal AT.
A highly significant intra-individual correlation between
the degree of hepatotoxicity during the first, second, and
third year of MT could be demonstrated (Figure 3).
Patients with mATMT >40 IU 1' did not differ signi-
ficantly from patients with mATMT <40 IU 1-' in respect to
gender, age at diagnosis, risk group (which includes previous
therapy), mean dose of MTX and 6MPm2, or mWBCMT
(Table II).
All patients in CCR with a mATMT > 80 IU 1', had
normal AT (<40IU1-') by one year off MT.
A liver biopsy was obtained from a 10-year-old girl, who
had a 10-20-fold rise in AT, a 2-3-fold rise in serum
bilirubin, normal prothrombin time, and negative serology
for HBsAg. The histology was normal. No other patients had
a biopsy.
Drug dosage
There was a significant relation between mATMT and
the percentual period of withdrawal of MTX (r = 0.34,
P<0.0001) and 6MP (r = 0.25, P = 0.003) during MT.
When patients with withdrawal of MTX or 6MP for more
than 10% of the length of MT were excluded, no significant
relation between mATMT and the dose of MTX and 6MP
could be found (MTX: r = -0.07, P = 0.34; 6MP:
r = -0.15, P = 0.11). The mean period of withdrawal of
MTX and/or 6MP (as previously defined) was 55% longer
for relapse patients with mATMT >40 IU 1- compared
to relapse patients with mATMT 40 IU 1'I (P<0.001) (Wil-
coxon's rank sum test). The major reason for drug-with-
drawal for > 10% of MT was hepatotoxicity.
Myelotoxicity
No significant relation could be demonstrated between
mATMT and mWBCMT (r = -0.03, P = 0.36). However, a
weak correlation existed between mAT3y and the rise in white
cell count following cessation of therapy (r = 0.24, P = 0.06).
A similar relation was found between mATMT and mANCMT.
However, it was not significant possibly due to the low
number of patients.
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Relapse rate
A total of 38 patients relapsed during follow-up, i.e. 24
haematological, eight CNS and six testicular relapses. Boys
had an increased relapse risk compared to girls (P = 0.003),
but did not differ in respect to duration of haematological
remission. Four and a half year probability of CCR did not
differ among the risk groups (SR, 0.62,; IR, 0.57; HR, 0.68);
neither did probability of haematological remission (SR,
0.71; IR, 0.74; HR, 0.81).
Table II Characteristics ofpatients without or with hepatotoxicitya
Total mATM <40 IU lT mATTMT>40IU1 '
No. patients Male:female
Mean age ± 1 s.d.
Risk groups HR/IR/SR
Relapses BM/CNS/TESTES
Mean WBCC
Mean dose of MTXd
Mean dose of 6MPd
Withdrawal of MTXC for
relapse patients
< 5% of the length of MT
>5 and < 10%
> 10%
Withdrawal of 6MP' for
relapse patients
< 5% of the length of MT
>5 and < 10%
> 10%
67:48
5yl lm±3y8m
56/39/20
24/8/6
4.2±1.1
15.4±4.1
63.7±10.1
25:21
5y8m ± 3y10m
21/19/6
15/4/2
4.3± 1.2
15.8±4.7
65.9± 12.0
13 (62%)
3 (14%)
5 (24%)
14 (67%)
5 (24%)
2 ( 9%)
42:27
6y2m ± 3y7m
35/20/14
9/4/4
4.1 ±0.9
15.1± 3.6
62.2± 8.3
7 (41%)
4 (24%)
6 (35%)
8 (47%)
2 (12%)
7 (41%)
aDefined as mATMT < or > 40 IU I-. bMean alanine aminotransferase during
maintenance therapy;
c x IO l- ;'"mgm-2; eNumbers and fractions of relapse-patients
with different degrees of drug-withdrawal due to toxicity or febrile illness.
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Patients who relapsed had significantly lower mATMT than
patients staying in remission (Wilcoxon's rank sum test: any
relapse, P = 0.03; haematological relapse, P = 0.03).
Stepwise multivariate regression analyses were done to ex-
plore the prognostic significance of combinations of possible
relapse predictors and to define a 'best-fit' model to predict
relapse. The variables analysed were: year of diagnosis
(1981-83 = 1 vs 1984-85 = 2), gender (male = 1, female =
2), age at diagnosis, WBC at diagnosis, the average dose of
MTX and 6MP, mWBCMT, and presence of hepatotoxicity
(mATMT < 40 I 1- = 1, mATMT >40 IU 1-' = 2). The best-
fit model to predict haematological relapse included hepato-
toxicity and mWBCMT (global P value <0.02). The best-fit
model to predict any relapse included gender and hepatotox-
icity (global P value <0.002). The coefficients of the co-
variates included in the models and their P values as uni- and
covariates are given in Table III. Identical 'best-fit' models
were achieved with stepwise backward elimination, all covar-
iates being forced into the model at the first step.
Figure 4 illustrates the positive relation between mATMT
and the probability of staying in remission. Figure 5 gives
Kaplan-Meier plots for the risk of haematological or any
relapse for patients stratified by a mATMT >40IUI-' or
<40 IU 1-'. Patients with a mATMT <40 IU I-' had a signi-
ficantly poorer outcome than did patients with mATMT
>40 IU 1-' with a 4.5 year probability of staying in
haematological remission of 0.63 and 0.83 (P = 0.03), and a
4.5 year probability of CCR of 0.50 and 0.70 (P = 0.06). The
favourable prognosis for patients with a mATMT >40 IU 1'
existed for all three risk groups, but was statistically
significant only in respect to haematological relapse for SR
patients (Table IV). A time-dependency of the prognostic
value of hepatotoxicity (i.e. a difference in the clinical
significance of hepatotoxicity during the first, second and
third years of MT) could not be demonstrated.
Discussion
The present study has confirmed the results of previous
reports of a high prevalence of hepatotoxicity in leukaemic
children receiving oral MTX/6MP therapy. Whereas a
number of these studies have set focus on the relation
between pathological liver function tests and the presence of
an abnormal liver histology (Nesbit et al., 1976; McIntosh et
al., 1977; Topley et al., 1979), the main purpose of the
present study was to explore the relation between relapse risk
and the rise in serum AT, the most commonly applied test to
detect liver dysfunction used by the departments participating
in the study.
The significant correlation between a rise in serum AT and
a reduced relapse risk could have several explanations, alone
or combined.
The large inter-individual differences in plasma concentra-
tion profiles after oral MT (Poplack et al., 1986) implies
different intensity of therapy, and children with adverse
pharmacokinetic parameters might lack hepatotoxicity and
be at increased risk for relapse, due to reduced systemic drug
exposure to both liver and lymphoblasts (Pinkel et al., 1971;
Craft et al., 1981). In support of hepatotoxicity reflecting
treatment intensity, we found a relation between mATMT and
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Figure 4 Probability of staying in complete or hematological
remission for subgroups of patients delimited by their mean
alanine aminotransferase. No. of patients in each group are given
on top of columns. E CCR, D Hematol. remission
the rise in white cell counts following cessation of therapy. In
addition, a correlation of hepatotoxicity to red blood cell and
hepatic accumulation of MTX-polyglutamates has been
demonstrated for MTX-therapy of leukaemia and psoriasis
(Schmeigelow et al., 1989; Hendel, 1985). Finally, patients
with hepatoxicity seem to have delayed systemic clearance of
MTX (Parker et al., 1980). If hepatotoxicity does reflect
treatment intensity, reduction of the doses of MTX and 6MP
for patients with abnormal liver function tests could carry an
increased relapse risk (Pinkel et al., 1971), which was also
indicated by the present study.
6MP undergoes hepatic metabolism and the first-pass effect
is considerable (Zimm et al., 1983). MTX-induced hepatotox-
icity, whether or not due to increased intestinal absorption or
reduced clearance, could therefore impair 6MP breakdown,
leading to treatment intensification. Along this line it has
been demonstrated that 6MP plasma peak-concentration and
AUC are increased with concurrent administration of MTX
and 6MP, compared to 6MP given alone (Balis et al., 1987).
Another metabolic explanation could be changes in the
activity of enzymes involved in MTX and 6MP metabolism
(Zimm et al., 1986; Lennard & Lilleyman, 1987; Rodenhuis
et al., 1987). Zimm et al. (1986) demonstrated significant
changes in lymphoblastic activity of enzymes involved in
6MP metabolism, when malignant lymphoblasts at diagnosis
and relapse were compared. It is not known whether a
parallel exists between such changes in the lymphoblastic
clone and the liver, in which case reduced hepatotoxicity
could parallel an increased risk for relapse. If such a correla-
tion exists, tapering of hepatotoxicity before the event of
relapse would be expected, but we found no such correlation.
Drug compliance cannot be excluded as a possible cont-
ributing factor to both a low mATMT and an increased risk
of relapse. However, a recent study indicated compliance to
be high among Danish leukaemic children (Schmiegelow et
al., 1990).
The relation between hepatotoxicity and relapse risk could
be due to a prolonged effect of previously given hepatotoxic
drugs, which could have influenced the amount of residual
Table III Stepwise multivariate proportional hazards regression models
Best-fit modelsfor
Haematological relapse risk Overall relapse risk
Global P value<0.02 Global P value < 0.002
Covariates Step 0 Step I Step 0 Step I
Gendera 0.16 0.11 0.003c 0.003 (-1.13)
Mean WBC during therapy 0.06 0.09C (0.28) 0.27 0.37
Hepatotoxicityb 0.03c 0.03 (-0.82) 0.06 0.03c (0.70)
'Male = 1, female = 2. bMean AT <40 IU 1` = l, mean AT >40 IU 1l = 2.
cVariable included in the model at the following step. Values are P values.
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Figure 5 Kaplan-Meier curves for probability of haemato-
logical or complete continuous remission for patients defined
by the mean alanine aminotransferase during maintenance
therapy (mATMT): mATMT <40 IU 1-' (lower curves), mATMT
>40 IU I1l (upper curves). P = 0.03 and P = 0.06, respectively,
for differences in hematological and complete remission. Patients
at risk: mATMT <40 IU I-': 1 year from remission, 43; 3 years,
28; 5 years, 12; mATMT >40 IUI-': 1 year, 62; 3 years, 42; 5
years, 17.
disease as well as liver tolerance to the hepatotoxic effect of
MTX and 6MP. But the finding of a correlation between
relapse risk and the degree of hepatotoxicity for all risk
groups, and in addition, this being statistically significant for
SR-patients who received only vincristine, prednisone and
HDM during induction and consolidation therapy, make this
explanation unlikely.
Lack of doctor compliance has been suggested as a possi-
ble risk factor (Peeters et al., 1988). In the present material
we found no difference in the dose of MTX for patients with
mATMT <40 or >40IU1'. Neither did the two groups
Table IV Probability of haematological or complete remission for
patients stratified by risk group and mean serum AT during
maintenance chemotherapy
Risk groups
SR IR HR
No. ofpatients with 21/35 19/20 6/14
mATMT<40 vs > 40 IU IV'
Probability of
haematological remissiona 0.57/0.80b 0.68/0.81 0.62/0.91
complete remission' 0.52/0.68 0.48/0.70 0.50/0.77
AT, alanine aminotransferase; mATMT, mean AT during main-
tenance chemotherapy; SR/IR/HR, standard/intermediate/high risk.
aEstimates at 4.5 year from achieved remission. bp<0.05.
differ in respect to the degree of leukopenia (mWBCMT) the
parameter most widely used to adjust MT. Thus, there was
no indication that patients lacking hepatotoxicity were
treated too leniently.
Other potentially hepatotoxic events like previous given
drugs, general anaesthesia (GA) or hepatitis could have
influenced the prevalence of rises in AT. However, as therapy
and the frequency of GA were the same for all patients
within the risk groups, and AT was the only abnormal liver
function test (among prothrombin time, bilirubin, phos-
phatase and AT) for >90% of the patients with mATMT
>40 IUI-1, these factors hardly significantly influenced the
relation between rises in AT and risk of relapse.
A major question is whether downward dose adjustments
are justified in the case of hepatotoxicity. A number of
previous reports have indicated a high incidence of serious
liver damage, but most of these patients received far higher
doses than presently used (Parker et al., 1980). The rises in
liver enzymes during MT are in most cases mild and tran-
sient with normalisation within a few months following the
cessation of therapy. For patients with severe liver dysfunc-
tion with affected prothrombin time, jaundice or very high
levels of liver enzymes, a liver biopsy may offer a guide to
whether dose modifications should take place, though often
no correlation exists between pathological liver function tests
and histology (Topley et al., 1979). Parker et al. (1980)
suggested that analysing plasma concentration profiles of
drugs could be helpful in determining dose modifications.
However, one should bear in mind that patients with delayed
drug clearance might be receiving the better treatment, which
could be jeopardised by dose reductions.
Until prospective studies have demonstrated that
hepatotoxicity is a greater threat to patients than the risk of
relapse, dose reductions do not seem warranted unless serious
liver damage have been confirmed by histology.
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